Valve-Sparing Aortic Root Replacement: Outcomes With Bicuspid Vs. Tricuspid Valves

Series finds short-term outcomes excellent, but BAV may be less durable


Early results for aortic root replacement with bicuspid aortic valve (BAV) reimplantation are similar to those with the better-established tricuspid aortic valve (TAV) reimplantation. However, outcomes between the two procedures diverge over time, indicating that long-term surveillance is needed for patients with a BAV reimplantation — and raising concern over its routine use.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

So conclude Cleveland Clinic investigators in their report of a retrospective case series published in the Journal of Thoracic and Cardiovascular Surgery (JTCVS) (2022;163[1]:51-63.e5).

“Our experience indicates that valve-preserving aortic root replacement for aortic aneurysm can be an attractive option for appropriate patients with either a tricuspid or a bicuspid aortic valve,” says senior author Lars Svensson, MD, PhD, Chair of Cleveland Clinic’s Heart, Vascular & Thoracic Institute. “But caution is needed with BAV reimplantation, to ensure careful selection of appropriate patients with bicuspid valves.”

Long-term outcomes for BAV reimplantation not well studied

Patients with aortic root dilatation — with or without dissection — are traditionally treated with a Bentall operation, which involves replacing the damaged portion of the aorta as well as the aortic valve with a biologic or mechanical prosthesis. But if the native valve is in good condition, Cleveland Clinic surgeons prefer reimplantation over replacement based on the world’s largest experience with reimplantation operations — over 1,200 to date. Evidence indicates that reimplantation lowers the risk of thromboembolic and bleeding complications, particularly in patients with connective tissue disease. It also may enhance aortic anulus stabilization, helping prevent further dilatation and aortic regurgitation — as well as a later surgery.

Although good evidence exists for excellent outcomes of valve reimplantation for patients with a TAV — e.g., 95% or better freedom from reoperation at 10 years — less is known about results with a BAV.

Study design and findings

Patients who underwent aortic root replacement with aortic valve reimplantation at Cleveland Clinic between January 2002 and July 2017 were included in the study. The cohort consisted of 607 adults, of whom 92 had a BAV reimplantation and 515 had a TAV reimplantation. To facilitate comparability of the two groups, 71 matched pairs were created using 28 preoperative variables.


Median follow-up of the BAV group was 2.8 years, with 25% followed for more than 4.7 years and 10% for more than 6.6 years.

In-hospital morbidity and mortality were very low and similar between the two groups, including one death (in the BAV group), one stroke (in the TAV group) and renal failure requiring dialysis in one patient in each group. The need for blood transfusion was similar between the groups.

At five years, survival rates were high and similar (100% in the BAV group, 95% in the TAV group, P = 0.07). However, concerning trends emerged in the BAV cohort (relative to the TAV cohort) over time, including the following:

  • Greater aortic regurgitation that increased over time
  • Higher mean gradient, which was evident from the outset postoperatively
  • Less left ventricular reverse remodeling
  • More aortic valve reoperations
  • More frequent pacemaker requirements

Weighing BAV reimplantation against alternatives

According to Dr. Svensson, the jury is still out on how valve reimplantation stacks up against other alternatives, such as a root remodeling operation, for a given patient with a BAV. He points out that determining the best aortic valve option is especially important for young patients. While some argue that at least offering them a good option for 10 or 15 years is reasonable, this approach makes it more likely the patient will need another operation when older and likely at higher risk.

“Longer-term follow-up and meta-analysis of data from multiple institutions are needed to determine whether BAV reimplantation measures up to the traditional Bentall operation with a mechanical or biological valve,” he advises.


Optimizing reimplantation

The article describes technical considerations that, in the experience of Cleveland Clinic surgeons, contribute to the success of a durable BAV or TAV reimplantation procedure. In brief, they recommend special attention to the following, known as the CLASS schema:

  • Commissures. Rather than measuring cusp heights to size the tube graft, commissure heights and leaflet coaptation are deemed more important.
  • Leaflets. To achieve optimal alignment of the aortic cusps, Cleveland Clinic surgeons most often employ a figure-of-8 over-and-over cusp apposition stitch at the commissure.
  • Anulus. As the aortic anulus is often too large, the left ventricular outflow tract is brought to a normal size by tying about 10 pledgeted graft sutures over a Hegar dilator sized according to patient sex and body size.
  • Sinuses and sinutubular junction. To create neosinuses when implanting a TAV, a large (30-32 mm) graft is used. For BAV, tension is needed on the cusps, requiring a larger graft size.

Implications for advising patients

“Reimplantation procedures have been well received by patients at the time of surgical intervention on the aorta,” observes study co-author Brian Griffin, MD, Section Head of Cardiovascular Imaging at Cleveland Clinic. “It’s not surprising that BAV reimplantation would have a less optimal long-term outcome than TAV reimplantation, given the inherent abnormality of the bicuspid valve. Notwithstanding the higher complication rate described in our study, BAV reimplantation has a role in management of individual patients, especially those who wish to avoid mechanical valve replacement and the need for long-term anticoagulation.”

Yet BAV reimplantation is an option best deployed by experienced centers and in well-selected patients. “In view of this study’s results and the fact that reimplantation is so technically demanding and requires more surgeon expertise,” Dr. Svensson concludes, “mechanical valves may be the best option for younger patients undergoing root surgery and at centers that lack expertise with reimplantation operations.”

Related Articles

completed mitral valve repair
Mitral Valve Re-Repair for Degenerative Disease Found Safe and Durable

Cleveland Clinic series supports re-repair as a favored option regardless of failure timing

illustration of a figure-of-8 stitch for aortic valve repair
Figure-of-8, Hitch-Up Stitch Is Safe and Durable in Bicuspid Aortic Valve Repair

Large retrospective study supports its addition to BAV repair toolbox at expert centers

3D transesophageal echocardiographic images
New Leaflet Modification Technique Curbs LVOT Obstruction Risk in Valve-in-Valve TMVR

Provides option for patients previously deemed anatomically unsuitable

illustration of mitral valve with male/female symbol overlay
Long-Term Outcomes of Mitral Valve Repair for Degenerative MR Worse in Women Than Men

A call for surgical guidelines to adopt sex-specific thresholds of LV size and function

Study Reveals Persistence of Later Surgical Referrals for Severe Degenerative Mitral Regurgitation

While mortality was unaffected, later surgery was associated with more reoperations

23-HVI-4417336 CQD 650×450
Aortic Valve Reimplantation Shows Long-Term Durability in Patients With Connective Tissue Disorders

Many young patients can avoid lifelong anticoagulation with a valve-sparing approach

illustration of mitral valve transcatheter edge-to-edge repair
The Two FDA-Approved M-TEER Systems Are Comparable at 1-Year Follow-Up, CLASP IID Data Show

And substudy reveals good outcomes with PASCAL system in patients with complex mitral valve anatomy

illustration of tricuspid valve regurgitation
TRILUMINATE Health Status Analysis: T-TEER Patients Likelier to Be ‘Alive and Well’ at 1 Year

Investigators conclude that improved self-reports go beyond possible placebo effect for severe TR